Cellares rebukes Bristol Myers' criticism of its cell therapy technology

PartnershipnegativeNegative

AI Analysis

Summary

Bristol Myers Squibb terminated its partnership with cell therapy manufacturing startup Cellares, citing inadequate commercial manufacturing technology. Cellares is defending itself against the criticism.

Outcome Details

Bristol Myers Squibb terminated partnership with Cellares, citing that Cellares' commercial manufacturing technology was not up to scratch

Importance:5/10

Sentiment:

-0.70

cell therapymanufacturingpartnership terminationtechnology dispute

Related Companies

$BMY

Read the original article

Published by Endpoints News on August 26, 2026 5:40 PM

Read Original